Skip to main content
Evidence Snapshot

Beta-2 adrenergic receptor

CHEMBL210 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:24:37Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL210
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Beta-2 adrenergic receptor as ChEMBL target CHEMBL210, mapped to UniProt P07550. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Beta-2 adrenergic receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL210
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P07550
Beta-2 adrenergic receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Beta-2 adrenergic receptor matters

As of 2026-09-13

Beta-2 adrenergic receptor is reviewed as Beta-2 adrenergic receptor (UniProt P07550); Beta-2 adrenergic receptor shows approved-linked disease relevance led by chronic obstructive pulmonary disease. 5 more disease programs remain visible in the same review block.; 21 linked drugs keep this evidence frame grounded.; the current evidence base includes 101 approved drugs, 6794 compounds, and 861 assays, with lead potency reaching pChEMBL 11.0.

Disease context
chronic obstructive pulmonary disease

Beta-2 adrenergic receptor shows approved-linked disease relevance led by chronic obstructive pulmonary disease. 5 more disease programs remain visible in the same review block. 21 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ABEDITEROL, ALBUTEROL, ALBUTEROL SULFATE.

Start review with chronic obstructive pulmonary disease because it currently carries approved-linked support. Linked drugs include ABEDITEROL, ALBUTEROL, ALBUTEROL SULFATE, ARFORMOTEROL TARTRATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 21 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 101 approved drugs, 6794 compounds, and 861 assays for this target. The dominant activity type is EC50. CHEMBL4847536 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL4847536 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine
101 approved pChEMBL 11.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Beta-2 adrenergic receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P07550, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why chronic obstructive pulmonary disease is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

6794
Total Compounds
861
Total Assays
101
Approved Drugs
IC50: 1628.0, KI: 1810.0, EC50: 1893.0, KD: 262.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4847536
 11.0 EC50 —
No preferred name
CHEMBL5570917
 10.9 EC50 —
No preferred name
CHEMBL2012522
 10.9 Ki —
No preferred name
CHEMBL4871708
 10.9 EC50 —
No preferred name
CHEMBL6067690
 10.9 Ki —

Approved Drugs

Structure Compound First Approval
BREXPIPRAZOLE
CHEMBL2105760
 2015
OLODATEROL
CHEMBL605846
 2014
INDACATEROL
CHEMBL1095777
 2009
SILODOSIN
CHEMBL24778
 2008
ARFORMOTEROL
CHEMBL1363
 2006
DARIFENACIN
CHEMBL1346
 2004
FORMOTEROL
CHEMBL1256786
 2001
LEVOSALBUTAMOL
CHEMBL1002
 1999
CARVEDILOL
CHEMBL723
 1995
SALMETEROL XINAFOATE
CHEMBL1082607
 1994
SALMETEROL
CHEMBL1263
 1994
SOTALOL
CHEMBL471
 1992
BISOPROLOL
CHEMBL645
 1992
PROPAFENONE
CHEMBL631
 1989
BETAXOLOL HYDROCHLORIDE
CHEMBL1691
 1985
LEVOBUNOLOL
CHEMBL1201237
 1985
LABETALOL
CHEMBL429
 1984
PINDOLOL
CHEMBL500
 1982
ATENOLOL
CHEMBL24
 1981
ALBUTEROL
CHEMBL714
 1981
ISOETHARINE
CHEMBL1201213
 1979
NADOLOL
CHEMBL521606
 1979
METOPROLOL
CHEMBL13
 1978
TIMOLOL
CHEMBL499
 1978
METAPROTERENOL
CHEMBL776
 1973
PROPRANOLOL HYDROCHLORIDE
CHEMBL1671
 1967
PROPRANOLOL
CHEMBL27
 1967
EPINEPHRINE
CHEMBL679
 1965
DEXAMETHASONE
CHEMBL384467
 1958
ISOPROTERENOL
CHEMBL434
 1956
ISOPROTERENOL HYDROCHLORIDE
CHEMBL1711
 1956
FENOTEROL
CHEMBL32800
 —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:24:37Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL210